Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
586
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

771
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
771
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thalamic Volume Asymmetry as a Potential Predictor of Vagus Nerve Stimulation Outcomes in Refractory Epilepsy.

Neurologia medico-chirurgica·2026
Same author

Acute normovolemic hemodilution and cardiac surgery-associated acute kidney injury: a retrospective cohort study.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2026
Same author

Clozapine for treatment-resistant schizophrenia with epilepsy: A case report.

PCN reports : psychiatry and clinical neurosciences·2026
Same author

Association Between Psychiatrists' Subjective Clinical Behavior Scores and Objective Quality Indicators Based on Discharge Prescriptions: A Nationwide Multicenter Study Based on the EGUIDE Project.

Neuropsychopharmacology reports·2026
Same author

Eight-Year Progression of Clinical Practice Implementation Following Guideline Training in the EGUIDE Project.

Neuropsychopharmacology reports·2026
Same author

Educational spillover effect within a cluster: Impact of guideline education for schizophrenia and major depressive disorder on psychiatrists' treatment behavior in a real-world multicenter study.

Asian journal of psychiatry·2026

Related Experiment Video

Updated: Jan 6, 2026

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.0K

Decreased electrodermal activity in patients with epilepsy.

Toru Horinouchi1, Kotaro Sakurai1, Nagisa Munekata2

  • 1Department of Psychiatry, Hokkaido University Graduate School of Medicine, 060-8638 West 5, North 14, North District, Sapporo City, Hokkaido, Japan.

Epilepsy & Behavior : E&B
|October 2, 2019
PubMed
Summary
This summary is machine-generated.

Electrodermal activity (EDA) is marginally decreased in epilepsy patients. Higher seizure frequency significantly correlates with lower EDA, suggesting potential for EDA-biofeedback therapy in epilepsy management.

Keywords:
Biofeedback therapyElectrodermal activityGalvanic skin responseIntractable epilepsyNoninvasiveSeizure numbers

More Related Videos

Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
06:28

Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems

Published on: September 27, 2024

3.1K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.1K

Related Experiment Videos

Last Updated: Jan 6, 2026

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.0K
Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems
06:28

Author Spotlight: Unraveling Seizure Dynamics and Novel Therapeutics for Status Epilepticus Using CMOS High-Density Microelectrode Array Systems

Published on: September 27, 2024

3.1K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.1K

Area of Science:

  • Neuroscience
  • Biomedical Engineering

Background:

  • Biofeedback therapy using electrodermal activity (EDA) is a novel noninvasive treatment for intractable epilepsy.
  • Understanding EDA characteristics in epilepsy patients is crucial for optimizing this therapy.

Purpose of the Study:

  • To assess and characterize electrodermal activity (EDA) in patients with epilepsy.
  • To compare EDA levels between epilepsy patients and healthy controls.
  • To investigate correlations between EDA and epilepsy-related factors.

Main Methods:

  • A cross-sectional observational study involving 22 epilepsy patients and 24 healthy controls.
  • Resting EDA was measured using a wristband device over 10 minutes under controlled conditions.
  • Data collected included demographic characteristics, EDA, state anxiety, epilepsy diagnosis, seizure frequency, disease duration, and antiepileptic drug (AED) count.

Main Results:

  • A decreasing trend in EDA was observed in epilepsy patients compared to controls, though not statistically significant (P=0.12).
  • A significant decrease in EDA was found in epilepsy patients with seizures compared to controls (P=0.036).
  • Seizure frequency showed a significant inverse correlation with EDA (ρ=-0.50, P=0.016), while disease duration and AED count did not correlate with EDA.

Conclusions:

  • Epilepsy patients exhibit marginally decreased EDA, with significantly lower EDA observed in those with higher seizure frequency.
  • These findings support the potential utility and appropriateness of electrodermal activity-biofeedback therapy for epilepsy management.